The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...
2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...
AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...
Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...
Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients ...
Results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps showed that AstraZeneca (AZN) and ...
The trial demonstrated patients treated with TEZSPIRE® (tezepelumab-ekko) had a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal ...
November 08, 2024--(BUSINESS WIRE)--Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that ...
TEZSPIRE demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo Positive high-level results from the ...